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Summary  48 
The World Health Organization European Region has one of the highest rates of multidrug-resistant (MDR) 49 
tuberculosis (TB) in the world, resulting in many vulnerable children getting exposed each year. Evidence for 50 
preventive therapy following MDR-TB exposure is limited and current guidance is conflicting. An online 51 
survey was performed to determine clinical practice in this region. Seventy-two clinicians from 25 countries 52 
participated. Practices related to screening and decision-making were highly variable. Just over half were 53 
providing preventive therapy for MDR-TB-exposed children; the only characteristic associated with provision 54 
was practice within the European Union (adjusted odds ratio: 4.07; 95% confidence interval: 1.33-12.5). 55 
  56 
  57 
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Background 58 
Multidrug-resistant (MDR) tuberculosis (TB) is caused by Mycobacterium tuberculosis with resistance to 59 
isoniazid and rifampicin.
1
 In the World Health Organization (WHO) European Region (defined at: 60 
http://www.who.int/about/regions/euro/en/) 16% of new TB cases and 48% of retreatment cases were 61 
estimated to be MDR-TB in 2015.
2
 Over 40,000 cases were notified that year,
2
 many of whom had contact 62 
with children. Young children are at high risk of progression to TB, including MDR-TB, following exposure.
3,4
 63 
MDR-TB treatment is long, expensive and associated with significant adverse events.  64 
 65 
There is good evidence for the effectiveness of drug therapy for child contacts of drug-susceptible TB to 66 
prevent progression to TB disease.
5
 However, the evidence base for the management of child contacts of 67 
MDR-TB cases is less robust. National and international guidance is inconsistent and conflicting, with 68 
clinicians facing difficult management choices. To date, only limited data exist regarding the current 69 
management of paediatric MDR-TB contacts in clinical practice. We therefore aimed to document current 70 
practice across different countries in the WHO European Region. 71 
 72 
 73 
Methods 74 
From March-July 2014 a web-based survey was conducted to explore variations in the management of MDR-75 
TB-exposed children.
6
 We developed an online questionnaire in English and Russian capturing the following: 76 
respondent characteristics, screening practices, preventive therapy (PT) practices, and follow-up 77 
(Supplementary Materials). Participants were asked to define patient groups considered for PT, the PT 78 
regimens used and treatment duration. The questionnaire was piloted among five clinical experts within the 79 
Paediatric Tuberculosis Network European Trials Group (ptbnet).
7
   80 
 81 
A list of clinicians likely to be managing child MDR-TB contacts in the WHO European Region was compiled 82 
using the membership lists of ptbnet, the International Union Against Tuberculosis and Lung Disease 83 
Childhood TB Working Group, and the Childhood Subgroup of the WHO Stop TB Partnership. Each clinician 84 
was sent a personalised email requesting their participation, with the request to forward the invitation to 85 
relevant colleagues. Three reminder emails were sent during the study period (Supplementary Materials).  86 
To assess factors associated with PT provision, we used a multivariable stepwise logistic regression model. 87 
Variables with p<0.15 in the univariable analysis were included in the model. Statistical analyses were 88 
undertaken using Stata version 14.0 (StataCorp, College Station, U.S.). 89 
 90 
 91 
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Ethics Approval 92 
Under current UK National Research Ethics Service (NRES) regulations, Research Ethics Committee review is 93 
not required for research involving healthcare staff recruited as research participants by virtue of their 94 
professional role (Governance Arrangements for Research Ethics Committees, paragraph 2.3.13). 95 
Participation in the survey was voluntary. Participants were aware that they were participating in research, 96 
and that the results may be published.  97 
 98 
Results 99 
Of 176 specialists from 44 countries approached, 72 (41%) respondents from 25 countries participated in the 100 
survey, including 28 from 6 countries outside the EU/EEA (Figure 1). Of all respondents, 66/72 (92%) had >5 101 
years of experience working with TB; 59/72 (82%) were at senior level and 41/72 (57%) managed ≥3 child 102 
MDR-TB contacts a year. To guide the management of the contacts, in addition to clinical history and 103 
examination, most respondents used imaging: 42/72 (58%) chest x-rays, 21/72 (29%) both chest x-rays and 104 
computer tomography, 4/72 (6%) computer tomography only; the remaining 5/72 (7%) did not routinely use 105 
imaging. Nearly half (32/72;44%) stated routinely collecting respiratory specimens in asymptomatic children. 106 
Variable combinations of interferon-gamma release assays (IGRA) and skin tests were used to diagnose TB 107 
infection: 45/72 (63%) used both IGRA and skin tests, 23/72 (32%) skin tests only, 2/72 (3%) IGRA only and 108 
2/72 (3%) neither. Of the skin tests, the tuberculin skin test (TST) was most frequently used; the Diaskintest 109 
(using recombinant CFP-10/ESAT-6; Generium Pharmaceuticals, Moscow) was used by 11 respondents based 110 
in the Russian Federation, Belarus, Estonia and Ukraine. 111 
  112 
Of all 72 respondents, 42 (58%) stated they were providing PT to MDR-TB-exposed children. For children 113 
with evidence of TB infection, 18/42 (43%) clinicians were providing PT if additional risk factors were present 114 
(age <2 or <5 years, HIV-infection or immunocompromise); 24/42 (57%) were treating all TB-infected 115 
children. For children without evidence of TB infection, the majority of respondents (26/42;62%) were doing 116 
follow-up without PT, 12/42 (29%) were providing PT if risk factors were present, and 4/42 (10%) were 117 
treating all contacts. For PT, 31/42 (74%) used regimens tailored to the drug susceptibility pattern of the 118 
source case’s isolate, 9/42 (21%) used standardised regimens (i.e. independent of susceptibility results), and 119 
two used variable approaches depending on situation. Approximately half of the respondents (22/42;52%) 120 
were using two-drug regimens, fewer used ≥3 drugs (8/42;19%) or monotherapy (10/42;24%), and the 121 
remaining two decided on case by case. Variable combinations of ethambutol, pyrazinamide, high-dose 122 
isoniazid and levofloxacin/moxifloxacin were the most commonly reported regimens. Most respondents 123 
(30/42;71%) stated treating for 6 or 9 months (50% and 21%, respectively). Most clinicians were following 124 
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children up for two years or longer regardless of PT being used or not (30/42;71% and 61/72;85% 125 
respectively) (Supplementary Materials). 126 
 127 
In the multivariable model the only factor associated with the provision of PT was practice within the EU/EEA 128 
(vs. outside the EU/EEA) with an adjusted odds ratio of 4.07 (95% CI: 1.33-12.5; p=0.014; Table 1). 129 
 130 
 131 
Discussion and Conclusions 132 
The results highlight a wide spectrum of practice in the management of children exposed to MDR-TB in 133 
countries of the WHO European Region. Over half of clinicians reported using PT with varying indications and 134 
drug regimens. Practices regarding PT differed significantly between clinicians based within the EU/EEA and 135 
those based outside. The observed difference between EU/EAA and non-EU countries may be due to a more 136 
individualised approach to patient management in EU/EAA countries versus a more programmatic approach 137 
in non-EU countries with greater reliance on official national guidelines and WHO recommendations. 138 
 139 
In addition to marked heterogeneity regarding provision of PT, our data also indicate high variation in 140 
investigations performed in children with MDR-TB contact with somewhat surprisingly high proportion of CT 141 
scans and collection of respiratory specimens in asymptomatic children. These findings may be a reflection 142 
of the paucity of data to guide standard diagnostic approaches in these children, and indicate that clinicians 143 
may have a tendency for more ‘aggressive’ investigation strategies in MDR-TB contacts.   144 
 145 
A key component of the WHO End TB Strategy is the identification and treatment of TB infection,
8
 with 146 
modelling exercises suggesting that without addressing TB infection it will be impossible to eliminate TB 147 
globally.
9
 This is as true, if not more so, for MDR-TB as it is for drug-susceptible TB, as a smaller proportion of 148 
MDR-TB cases are identified and treated, and outcomes are much poorer. At least three funded trials 149 
investigating the treatment of MDR-TB contacts are currently underway, but results are not expected for 150 
several years. Observational studies suggest that the use of PT for MDR-TB can be safe and effective,
10
 but 151 
existing guidelines are highly variable. It is therefore not surprising that current practice across the WHO 152 
European Region is so inconsistent, and it appears likely that these inconsistencies will persist until 153 
international and national guidelines are harmonised. 154 
 155 
The survey was limited to clinicians managing child MDR-TB contacts in the WHO European Region who were 156 
identified and responded to the survey. Although we contacted a wide range of clinicians and included 157 
flexible answer options, it is likely that not all possible practices were captured. The survey only documents 158 
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reported practice, rather than capturing individual patient management. Despite these limitations, the 159 
results provide insight into the current management of paediatric MDR-TB contacts in EU/EAA and non-EU, 160 
countries and highlight the urgent need for stronger evidence to guide clinical decisions.   161 
 162 
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Table 1. Association between respondent characteristics and the provision of preventive therapy (n=72) 220 
 PT  
given  
(n) 
PT  
not given 
(n) 
Odds ratio  
(95% CI) 
P value Adjusted Odds ratio  
(95% CI) 
P value 
Experience of treating TB 
patients 
<10 years 13 10 Ref 0.83   
≥ 10 years 29 20 1.12 (0.41-3.06)    
Specialist TB doctor 
No 28 13 Ref 
0.05 
Ref 
0.51 
Yes 14 17 0.38 (0.14-1.04) 0.69 (0.23-2.09) 
Consultant level doctor 
No 6 7 Ref 
0.33 
 
 
Yes 36 23 1.83 (0.54-6.22)  
Number of MDR-TB child 
contacts managed per year 
<3 per year 19 12 Ref 0.66   
≥3 per year 23 18 0.81 (0.31-2.10)    
Country of respondent 
Outside EU/EEA 10 18 Ref 
0.002 
Ref 
0.014 
Within EU/ EEA 32 12 4.80 (1.59-14.5) 4.07 (1.33-12.5) 
CI: confidence interval; EEA: European Economic Area; MDR-TB: multidrug-resistant tuberculosis; PT: preventive therapy Ref: reference value; TB: 221 
tuberculosis. 222 
 223 
 224 
 225 
 226 
 227 
 228 
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Figure Legend 229 
 230 
Figure 1: Location of practice and number of survey respondents in countries in the World Health 231 
Organization European Region. Participating countries: Albania, Armenia, Austria, Belarus, Belgium, 232 
Bulgaria, Estonia, Finland, Germany, Greece, Ireland, Israel, Latvia, Lithuania, Malta, Moldova, Portugal, 233 
Romania, Russian Federation, Spain, Sweden, Switzerland, Tajikistan, UK, Ukraine 234 
 235 
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II.   Flowchart of the strategy to identify specialists who are likely to manage child contacts of 
multidrug-resistant tuberculosis cases in Europe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ptbnet 
database 
(n=77) 
Childhood subgroup of 
the Stop TB partnership 
(n=17) 
Childhood tuberculosis 
working group of the 
International union against 
TB and lung disease (n=28) 
In countries with only 
one or two specialists 
identified, specialists 
from that country 
contacted by personal 
email and asked if they 
could provide contact 
details for additional 
specialists   
List of specialists 
compiled and 
duplicates removed 
(n=105) 
Final list of specialists 
contacted (n=176) 
number of countries 
(n=44) 
Personal 
contacts, 
recommendation 
and suggestions 
Survey responders 
(n=72), number of 
countries (n=25) 
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III.   Tables: Results of responses to the survey questions 
Table 1: Characteristics of respondents to the questionnaire (n=72) 
Country of respondent 
Albania 1 
Armenia 4 
Austria 2 
Belarus 1 
Belgium 1 
Bulgaria 1 
Estonia 4 
Finland 3 
Germany 4 
Greece 1 
Ireland 1 
Israel 1 
Latvia 6 
Lithuania 2 
Malta 1 
Moldova 3 
Portugal 2 
Romania 5 
Russian Federation 8 
Spain 6 
Sweden 3 
Switzerland 3 
Tajikistan 1 
UK 3 
Ukraine 5 
Duration of experience with TB 
<1 year 1 
1-2 years 1 
2-5 years  4 
5-10 years 17 
>10 years 49 
Type of Doctor 
Paediatric Doctor 1 
Paediatric Infectious Diseases Doctor 20 
Paediatric TB Doctor 26 
Adult TB Doctor 6 
Paediatric Respiratory Doctor 11 
Adult Respiratory Doctor 4 
Adult Physician 1 
Other
1
 3 
Level of Doctor 
Consultant/Attending/Senior 59 
Middle/Resident/Registrar 10 
Junior/Intern 0 
Other
1
 3 
Where are child MDR-TB contacts seen? 
Dedicated TB centre 40 
Paediatric Hospital 22 
Paediatric part of general hospital 9 
General hospital 1 
Primary care/community clinic/polyclinic 6 
TB sanatorium 4 
How many child MDR-TB contacts, on average, do you 
see a year  
Infrequently 18 
1-2 per year 13 
3-5 per year 9 
5-10 per year 12 
>10 per year 20 
Language of survey used  
English 48 
Russian 24 
1
Researchers/epidemiologists/public health doctors 
20
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Table 2: Identification and investigation of child contacts of multidrug-resistant tuberculosis source cases 
(n=72) 
 
Following the adult MDR-TB diagnosis, how are child 
contacts identified? 
Questioning MDR-TB source case 40 
Questioning the source case and home visit 30 
Other
1
 2 
Who refers child contacts to your services? (more than 
one answer possible) 
Nurses/doctors within the TB programme 54 
School nurses 8 
Primary care/family doctors 26 
Paediatric Doctors 28 
Adult doctors 27 
Self-referral 24 
Other
2
 8 
In an asymptomatic child MDR-TB contact, which tests 
do you commonly use to make a decision on further 
management? (more than one answer possible) 
None 1 
IGRA 47 
TST 67 
Diaskintest 11 
CXR 63 
CT scan 25 
Gastric washings/aspirates 24 
Expectorated sputum 24 
Induced sputum 16 
Broncho-alveolar lavage 12 
Other
3
 5 
With regards TST/IGRA, in which circumstances do you 
give preventive therapy for child MDR-TB contacts? 
Never given 30 
TST/IGRA not used to make a decision 1 
TST alone positive 4 
IGRA alone positive 2 
Both TST and IGRA positive 6 
Either TST or IGRA positive 27 
Other
4
 5 
For child MDR-TB contacts with evidence of M. 
tuberculosis infection (based on positive TST and/or 
IGRA), who do you give preventive therapy? 
Never given 30 
Children <2 years 2 
Children <5 years 8 
All children  24 
Children with immunosuppression 10 
Other
5
 5 
In which child MDR-TB contacts do you give preventive 
therapy without evidence of M. tuberculosis infection? 
Never given 30 
Preventive therapy only given if evidence of infection 26 
Children <1 year 1 
Children <2 years 5 
Children <5 years 2 
All children  4 
Children with immunosuppression 6 
Other
6
 2 
If you start preventive therapy in children with negative 
TST/IGRA tests initially, do you ever repeat the tests? 
Never given 30 
TST is repeated after 2 months 5 
IGRA is repeated after 2 months 2 
Both TST and IGRA are repeated after 2 months 20 
If preventive therapy is started a full course is given 11 
Other
7
 7 
 
1
Identification through other referral pathways; 
2
Public health doctors/researchers; 
3
Blood tests for inflammatory markers, full blood 
count, HIV test; 
4
The decision is based on the age of the child; 
5
Decision made on a case by case basis; 
6
Dependant on BCG status; 
7
Depends on clinical circumstances and BCG status 
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Table 3: Treatment of child contacts of multidrug-resistant tuberculosis source cases (n=72) 
What regimen do you use for preventive therapy in child 
MDR-TB contacts? 
Never given 30 
Standard regimen with 1 drug 5 
Standard regimen with 2 drugs 3 
Standard regimen with >2 drugs 1 
Tailored regimen with 1 drug 5 
Tailored regimen with 2 drugs 19 
Tailored regimen with >2 drugs 7 
Other
1
 2 
If you use a standard regimen, which drugs do you use? 
Standard dose isoniazid 3 
High dose isoniazid 4 
Ethambutol 4 
Pyrazinamide 4 
Levofloxacin 2 
Moxifloxacin 2 
If you use a tailored regimen, which drugs do you use? 
Standard dose isoniazid 4 
High dose isoniazid 13 
Ethambutol 24 
Pyrazinamide 22 
Ofloxacin 5 
Ciprofloxacin 3 
Levofloxacin 13 
Moxifloxacin 15 
Gatifloxacin 1 
Ethionamide 11 
Cycloserine 6 
PAS 3 
Linezolid 5 
How long do you generally treat children with 
preventive therapy after exposure to MDR-TB? 
3 months 4 
6 months 21 
9 months 9 
12 months 3 
18 months 1 
24 months 1 
Other
1
 4 
How is preventive therapy delivered to the child? 
Child is admitted to hospital 4 
Child is admitted to sanatorium 10 
The child is taken daily to the clinic 5 
A healthcare worker visits the child daily 13 
The parents give the preventive therapy 32 
Other
2
 3 
 
1
Varies with clinical situation; 
2
School supervision/nurse in a children’s home  
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Table 4: Follow up for child contacts of multidrug-resistant tuberculosis source cases (n=72) 
For children on preventive therapy at which time 
points do you follow them up? 
No preventive therapy given 30 
By one month  25 
At 2 months  19 
At 3 months 26 
At 4 months 13 
At 6 months 29 
At 9 months 12 
At 12 months 15 
When needed 13 
Other
1
 5 
For child MDR-TB contacts NOT on preventive therapy 
when are they followed up? 
No follow up 3 
By one month 16 
At 2 months  20 
At 3 months 40 
At 4 months 2 
At 6 months 45 
At 9 months 11 
At 12 months 28 
When needed 28 
Other
1
 3  
If you do chest x-rays for children on preventive 
therapy, at which time points do you do them? 
No preventive therapy given 30 
By one month 1 
At 2 months  3 
At 3 months 17 
At 4 months 1 
At 6 months 19 
At 9 months 2 
At 12 months 14 
When needed 20 
Other
1
 2 
If you do chest x-rays for children NOT on preventive 
therapy, at which time points do you do them? 
No chest x-rays done 2 
By one month 8 
At 2 months  5 
At 3 months 27 
At 4 months 0 
At 6 months 39 
At 9 months 5 
At 12 months 29 
When needed 30 
Other
1
 1 
For children on preventive therapy after exposure to 
MDR-TB, how long do you routinely follow them up 
for? 
No preventive therapy given 30 
Until the end of the preventive therapy 2 
Until 3 months after preventive therapy ends 2 
Until 6 months after preventive therapy ends 7 
Until 12 months after preventive therapy ends 1 
Until 2 years after preventive therapy ends 22 
>2 years after preventive therapy ends 8 
For children NOT on preventive therapy, how long do 
you routinely follow them up for? 
No follow up 0 
For 3 months 3 
For 6 months 3 
For 12 months 4 
For 2 years 42 
For >2 years 19 
 
1
Seen daily in sanatorium, seen every month, depends on age of child 
23
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